ROHTO PHARMACEUTICAL CO.,LTD.【JP:4527】Stock Price

Rohto Pharmaceutical operates a diverse range of businesses in the health and beauty care sector. Its main business segments include eye care products, skin care products, oral medications, and other products. Specifically, the company manufactures and sells eye drops, eye wash solutions, topical medications, lip balms, sunscreen, functional cosmetics, gastrointestinal medicines, herbal remedies, supplements, and in vitro diagnostic tests.

In Japan, Rohto Pharmaceutical and its subsidiaries offer eye care, skin care, and oral medication products. Rohto Nitten Corporation specializes in the manufacture and sale of eye care products. In the United States, Mentholatum Company focuses on skin care products. In Europe, Mentholatum UK manufactures and sells skin care products. In the Asia-Pacific region, Mentholatum Asia-Pacific and Mentholatum China offer eye care and skin care products, while Uyangsan International handles oral medication products.

Rohto Pharmaceutical maintains subsidiaries and affiliated companies worldwide, providing region-specific products tailored to each market. This approach enables the company to develop products and implement sales strategies that meet local market needs while advancing its global business operations.

Rohto Pharmaceutical has established a growth strategy centered on health and beauty. In its medium-term management plan, the company positions self-care and self-medication as core businesses, while designating professional medication as a growth investment business. Through this approach, the company aims to provide comprehensive coverage across the health spectrum—from preventive care and pre-disease states through mild conditions to serious illness.

The company's growth strategy is built on three fundamental pillars: strengthening business profitability, deepening and expanding technological and product capabilities, and establishing the foundation for medical business operations. Through these initiatives, the company aims to realize a well-being society and continue providing products and services that support healthy and fulfilling lives.

Specifically, the company focuses on six business areas: OTC pharmaceuticals, skincare, functional foods, medical ophthalmology, regenerative medicine, and contract development and manufacturing. The company pursues sustainable growth through technological innovation and market expansion in these fields.

Digital transformation (DX) is also a key component of the strategy. By leveraging customer data to provide healthcare services tailored to individual needs, the company aims to build new business models. Additionally, the company is strengthening its global expansion, with particular focus on growth in Asian markets.

Rohto Pharmaceutical is advancing initiatives toward a sustainable society from an SDGs perspective. By addressing five material issues—including the realization of well-being through business operations, enhancement of corporate value, and contribution to the global environment—the company is working toward coexistence with society.